Clinical Trial

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

Study acronym: PALM-PAH
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-27
Trial Details
NCT Number NCT07481981
Lead Sponsor Insmed Incorporated
Conditions Pulmonary Arterial Hypertension
Enrollment 344 participants
Start Date 2026-06-26
Primary Completion 2028-12-28 (estimated)
Study Completion 2029-01-28 (estimated)
Updated on ClinicalTrials.gov 2026-06-10